Nan Fung Trinity HK Ltd. Boosts Position in Soleno Therapeutics, Inc. $SLNO

Nan Fung Trinity HK Ltd. raised its stake in Soleno Therapeutics, Inc. (NASDAQ:SLNO) by 20.3% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 123,850 shares of the company’s stock after purchasing an additional 20,900 shares during the period. Nan Fung Trinity HK Ltd.’s holdings in Soleno Therapeutics were worth $8,372,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of Soleno Therapeutics by 1.1% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 17,360 shares of the company’s stock valued at $1,242,000 after buying an additional 189 shares in the last quarter. Raymond James Financial Inc. acquired a new position in Soleno Therapeutics in the second quarter valued at $25,000. New York State Common Retirement Fund boosted its stake in Soleno Therapeutics by 2.4% in the third quarter. New York State Common Retirement Fund now owns 15,600 shares of the company’s stock valued at $1,055,000 after acquiring an additional 360 shares in the last quarter. Nisa Investment Advisors LLC increased its position in shares of Soleno Therapeutics by 287.8% during the second quarter. Nisa Investment Advisors LLC now owns 539 shares of the company’s stock worth $45,000 after purchasing an additional 400 shares in the last quarter. Finally, Osaic Holdings Inc. lifted its holdings in shares of Soleno Therapeutics by 97.7% in the 2nd quarter. Osaic Holdings Inc. now owns 856 shares of the company’s stock valued at $72,000 after purchasing an additional 423 shares during the last quarter. Hedge funds and other institutional investors own 97.42% of the company’s stock.

Soleno Therapeutics Price Performance

Shares of SLNO opened at $38.56 on Friday. The company has a current ratio of 16.08, a quick ratio of 15.88 and a debt-to-equity ratio of 0.10. The stock’s 50 day moving average is $46.58 and its two-hundred day moving average is $59.80. Soleno Therapeutics, Inc. has a twelve month low of $37.95 and a twelve month high of $90.32. The firm has a market capitalization of $2.07 billion, a PE ratio of -20.96 and a beta of -3.12.

Soleno Therapeutics (NASDAQ:SLNO) last posted its quarterly earnings results on Tuesday, November 4th. The company reported $0.47 EPS for the quarter, beating the consensus estimate of $0.08 by $0.39. The business had revenue of $66.02 million during the quarter, compared to analyst estimates of $47.46 million. Research analysts anticipate that Soleno Therapeutics, Inc. will post -3.72 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on SLNO. Zacks Research upgraded Soleno Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Monday, January 5th. The Goldman Sachs Group set a $125.00 price objective on Soleno Therapeutics and gave the company a “buy” rating in a report on Tuesday, October 7th. Wolfe Research set a $60.00 target price on shares of Soleno Therapeutics in a report on Monday, January 12th. Robert W. Baird set a $107.00 price target on shares of Soleno Therapeutics in a research note on Tuesday, January 13th. Finally, Wells Fargo & Company restated an “overweight” rating and issued a $114.00 price objective (up from $106.00) on shares of Soleno Therapeutics in a research note on Tuesday, January 20th. Two investment analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Soleno Therapeutics currently has a consensus rating of “Buy” and an average target price of $110.62.

About Soleno Therapeutics

Soleno Therapeutics, Inc is a clinical?stage biopharmaceutical company focused on the development and commercialization of therapies for rare and orphan diseases. Headquartered in Redwood City, California, Soleno leverages a precision medicine approach to identify and advance small?molecule treatments that address underlying genetic and metabolic dysfunctions. The company’s scientific strategy centers on repurposing and reformulating existing compounds to maximize therapeutic benefit in underserved patient populations.

The company’s lead candidate, diazoxide choline controlled release (DCCR), is being investigated for the treatment of Prader-Willi syndrome (PWS), a complex neurodevelopmental disorder characterized by insatiable appetite, hormonal imbalances and behavioral challenges.